Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Macugen Observational Study

This study has been terminated.
(See termination reason in detailed description.)
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00735943
First received: August 14, 2008
Last updated: August 26, 2011
Last verified: August 2011
  Purpose

The objective of this observational study is to evaluate the effectiveness and safety of Macugen for treatment of wet age-related macular degeneration (AMD) in Indian patients.Prospective, Observational, Non-interventional Study. The period of observation for the study will be 1 year


Condition Intervention
Vascular Endothelial Growth Factor
Macular Degeneration
Other: No intervention

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Macugen Observational Study

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Percentage of Participants Showing Stabilization, Improvement or Deterioration of Visual Acuity (VA) [ Time Frame: Baseline through 12 months or last follow-up visit before study termination ] [ Designated as safety issue: No ]
    VA was measured using ETDRS (Early Treatment Diabetic Retinopathy Study) chart at 4 meter distance, at 1 meter distance (if participant's VA was poor) or verifying if the participant was able only to count fingers, to perceive hand motion or light. VA was assessed as the number of ETDRS letters correctly read. VA statuses were defined as: Stabilization: loss of less than 15 letters in the best corrected VA (BCVA); Improvement: gain of more than or equal to 15 letters in the BCVA; Deterioration: loss of more than or equal to 15 letters in the BCVA.

  • Average Number of Injections to Achieve Stabilization of VA [ Time Frame: 12 months or last follow-up visit before study termination ] [ Designated as safety issue: No ]
    Stabilization of VA was defined as loss of less than 15 letters in the BCVA. For each participant, number of injections before reaching the first "stabilization in VA" (considered as an event) was counted. For participant having no event, the time to the number of injections to reach an event was unobserved at the number of injections before the last follow up.

  • Median Number of Injections to Achieve Stabilization of VA [ Time Frame: 12 months or last follow-up visit before study termination ] [ Designated as safety issue: No ]
    Stabilization of VA was defined as loss of less than 15 letters in the BCVA. Median number of injections to achieve stabilization of VA was estimated via the Kaplan Meier method. For each participant, number of injections before reaching the first "stabilization in VA" (considered as an event) was counted. For participant having no event, the time to the number of injections to reach an event was unobserved at the number of injections before the last follow up.


Secondary Outcome Measures:
  • Percentage of Participants Receiving Macugen Monotherapy Versus Those Receiving a Combination Therapy [ Time Frame: 12 months or last follow-up visit before study termination ] [ Designated as safety issue: No ]
    Macugen monotherapy: referred to participants receiving Macugen in the study eye during the study that is (i.e.) participants without any concomitant drug treatment or nondrug treatment for the study eye during the study. Combination therapy: referred to participants receiving combination therapy in the study eye (during the study) i.e. participants with any concomitant drug treatment or nondrug treatment for the study eye during the study.

  • Percentage of Participants Showing Improvement in Optical Coherence Tomography (OCT) Parameters [ Time Frame: 12 months or last follow-up visit before study termination ] [ Designated as safety issue: No ]
    OCT, a noninvasive, noncontact, transpupillary imaging technology, was utilized to image retinal structures in vivo with a resolution of 10 to 17 microns. The anatomic layers within the retina, retinal thickness could be measured. Improvement in OCT parameters was defined as a reduction of more than or equal to 100 microns in the central macular thickness (Center subfield).

  • Percentage of Participants Showing Improvement in Fundus Fluorescein Angiography (FFA) Parameters [ Time Frame: 12 months or last follow-up visit before study termination ] [ Designated as safety issue: No ]
    A fluorescein angiogram provides information about the condition of the retina. Improvement in FFA parameters was defined as absence of progression of the lesion or decrease in the size of the lesion and absence of new lesions on FFA i.e. change in lesion size from baseline must be less than or equal to 0 disc area(DA) and no new lesions.

  • Percentage of Participants With Early Lesions Showing Stabilization and Improvement of VA [ Time Frame: 12 months or last follow-up visit before study termination ] [ Designated as safety issue: No ]
    Early lesions were defined by any 2 of the following criteria: occult lesion diagnosed on FFA; baseline VA of more than or equal to 54 ETDRS letters; lesion size of less than 2DA on FFA. Stabilization of VA was defined as loss of less than 15 letters in the BCVA. Improvement in the VA was defined as gain of more than or equal to 15 letters in the BCVA.

  • Average Number of Injections to Achieve Stabilization of VA in Participants With Early Lesions [ Time Frame: 12 months or last follow-up visit before study termination ] [ Designated as safety issue: No ]
    Stabilization of VA was defined as loss of less than 15 letters in the BCVA. For each participant, number of injections before reaching the first "stabilization in VA" (considered as an event) was counted. For participant having no event, the time to the number of injections to reach an event was unobserved at the number of injections before the last follow up.

  • Median Number of Injections to Achieve Stabilization of VA in Participants With Early Lesions [ Time Frame: 12 months or last follow-up visit before study termination ] [ Designated as safety issue: No ]
    Stabilization of VA was defined as loss of less than 15 letters in the BCVA. Median number of injections to achieve stabilization of VA in participants with early lesions was estimated via the Kaplan Meier method. For each participant, number of injections before reaching the first "stabilization in VA" (considered as an event) was counted. For participant having no event, the time to the number of injections to reach an event was unobserved at the number of injections before the last follow up.

  • Percentage of Participants With Occult or Minimally Classic and Classic Lesions Showing Stabilization and Improvement in VA [ Time Frame: 12 months or last follow-up visit before study termination ] [ Designated as safety issue: No ]
    FFA was utilized to characterize the lesions as follows: Classic lesion: more than 50% of the lesion had a well-demarcated area of hyperfluorescence; minimally classic lesion: less than or equal to 50% of lesion had well-demarcated area of hyperfluorescence; occult lesion: lesion with no well demarcated borders. VA statuses were defined as: stabilization: loss of less than 15 letters in the BCVA; improvement: gain of more than or equal to 15 letters in the BCVA.

  • Percentage of Participants Who Were Treatment Naive When Started on Macugen Versus Those Previously Treated by Any Other Therapy Except Macugen [ Time Frame: 12 months or last follow-up visit before study termination ] [ Designated as safety issue: No ]
    Participants were considered treatment naive when started on Macugen and without any previous drug or non drug treatment administered to the study eye. Participants were considered previously treated by any other therapy if received any other drug or non drug treatment to the study eye except Macugen.

  • Percentage of Participants Showing Stabilization or Improvement in VA in the Subgroup Previously Treated by Other Therapy [ Time Frame: 12 months or last follow-up visit before study termination ] [ Designated as safety issue: No ]
    VA was measured using ETDRS chart at 4 meter distance, at 1 meter distance (if patient's VA was poor) or verifying if the patient was able only to count fingers, to perceive hand motion or light. VA was measured as the number of ETDRS letters correctly read. VA statuses were defined as: stabilization: loss of less than 15 letters in the BCVA; improvement: gain of more than 15 letters in the BCVA.

  • Percentage of Participants Showing Improvement in OCT in the Subgroup Previously Treated by Other Therapy [ Time Frame: 12 months or last follow-up visit before study termination ] [ Designated as safety issue: No ]
    OCT, a noninvasive, noncontact, transpupillary imaging technology, was utilized to image retinal structures in vivo with a resolution of 10 to 17 microns. The anatomic layers within the retina, retinal thickness could be measured. Improvement in OCT parameters was defined as a reduction of more than or equal to 100 microns in the central macular thickness (Center subfield). Improvement in OCT parameters was measured based on this single parameter.

  • Percentage of Participants Showing Improvement in OCT in the Subgroup Which Were Not Treatment Naive [ Time Frame: 12 months or last follow-up visit before study termination ] [ Designated as safety issue: No ]
    OCT, a noninvasive, noncontact, transpupillary imaging technology, was utilized to image retinal structures in vivo with a resolution of 10 to 17 microns. The anatomic layers within the retina, retinal thickness could be measured. Improvement in OCT parameters was defined as a reduction of more than or equal to 100 microns in the central macular thickness (Center subfield). Improvement in OCT parameters was measured based on this single parameter.


Enrollment: 22
Study Start Date: November 2008
Study Completion Date: August 2010
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: No intervention
    No intervention
Detailed Description:

To be eligible for enrollment in this study, patients must receive the first injection of Macugen intravitreal in at least one eye for treatment of wet age-related macular degeneration (AMD). The decision to prescribe Macugen will necessarily precede and will be independent of the decision to enroll patient into the study.

If both eyes of a patient receive injection Macugen, only one eye will be included in the study. If both eyes receive first injection Macugen after initiation of the study, only the first treated eye will be included in the analysis. If one eye has already received Macugen when the study starts and the second eye receives injection after the study initiation, the second eye will be included in the analysis.

The study was prematurely discontinued due to delay in meeting pre-defined protocol recruitment milestones on August 30, 2010. There were no safety concerns regarding the study in the decision to terminate the trial.

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

To be eligible for enrollment in this study, patients must receive the first injection of Macugen intravitreal in at least one eye for treatment of wet age-related macular degeneration (AMD).

Criteria

Inclusion Criteria:

  • To be eligible for enrollment in this study, patients must receive the first injection of Macugen intravitreal in at least one eye for treatment of wet age-related macular degeneration (AMD).

Exclusion Criteria:

  • Active or suspected ocular or periocular infection.
  • Known hypersensitivity to pegaptanib sodium or any other excipient in this product.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00735943

Locations
India
Pfizer Investigational Site
Navrangpura, Ahemdabad, Gujarat, India, 380009
Pfizer Investigational Site
Gurgaon, Haryana, India, 122 002
Pfizer Investigational Site
Cochin, Kerala, India, 682 015
Pfizer Investigational Site
Mumbai, Maharashtra, India, 400 054
Pfizer Investigational Site
Jaipur, Rajasthan, India, 302 004
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00735943     History of Changes
Other Study ID Numbers: A5751031
Study First Received: August 14, 2008
Results First Received: July 21, 2011
Last Updated: August 26, 2011
Health Authority: India: Institutional Review Board

Keywords provided by Pfizer:
Pegaptanib
macular degeneration
vascular endothelial growth factor

Additional relevant MeSH terms:
Macular Degeneration
Eye Diseases
Retinal Degeneration
Retinal Diseases

ClinicalTrials.gov processed this record on November 20, 2014